Table 6

Costs, incremental costs and cost-effectiveness ratios* for ranibizumab treatment compared with no ranibizumab treatment for a 67-year old woman over a 10-year time horizon, under different treatment effectiveness and dosing scenarios.

Scenario

Cost

Cost per case of blindness prevented

Cost per blind-year prevented

Cost per QALY gained

Ranibizumab treatment

No ranibizumab treatment

Difference

$

$

$

$

$

$

Base-case scenario

Including caregiver costs

Ranibizumab cost

Wholesale price

205,800

238,300

-32,500

Dominant^†

Dominant

Dominant

Bevacizumab price

147,100

238,300

-91,100

Dominant

Dominant

Dominant

Excluding caregiver costs

Ranibizumab cost

Wholesale price

88,800

26,300

62,400

217,700

29,200

91,900

Bevacizumab price

30,100

26,300

3,800

13,200

1,800

5,600

Sustained-effect scenario

Including caregiver costs

Ranibizumab cost

Wholesale price

144,400

238,300

-93,800

Dominant

Dominant

Dominant

Bevacizumab price

125,500

238,300

-112,700

Dominant

Dominant

Dominant

Excluding caregiver costs

Ranibizumab cost

Wholesale price

42,200

26,300

15,900

41,100

6,400

20,300

Bevacizumab price

23,300

26,300

-3,000

Dominant

Dominant

Dominant

Non-sustained-effect scenario

Including caregiver costs

Ranibizumab cost

Wholesale price

209,800

238,300

-28,500

Dominant

Dominant

Dominant

Bevacizumab price

164,800

238,300

-73,500

Dominant

Dominant

Dominant

Excluding caregiver costs

Ranibizumab cost

Wholesale price

74,000

26,300

47,700

218,600

27,900

86,900

Bevacizumab price

29,100

26,300

2,700

12,500

1,600

5,000

*Costs are in 2004 U.S. dollars and were rounded.

Costs, blind-years and QALYs were discounted at 3% per annum

† Dominant: Ranibizumab treatment was more effective and cost less than the no ranibizumab strategy

Hurley et al. Cost Effectiveness and Resource Allocation 2008 6:12   doi:10.1186/1478-7547-6-12